Company Karyopharm Therapeutics Inc.

Equities

KPTI

US48576U1060

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Karyopharm Therapeutics Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Real-time Estimate Cboe BZX Other stock markets 10:59:37 2024-04-16 am EDT			5-day change	1st Jan Change
1.145 ^USD	-0.87%		-14.93%	+31.79%

Mar. 13	Transcript : Karyopharm Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM
Feb. 29	Transcript : Karyopharm Therapeutics Inc., Q4 2023 Earnings Call, Feb 29, 2024

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Companyâs product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.

Number of employees: 325

USD in Million	2022	Weight	2023	Weight	Delta
Drugs 100.0 %	157	100.0 %	146	100.0 %	-7.03%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	157	100.0 %	146	100.0 %	-7.03%

Managers	Title	Age	Since
Richard Paulson CEO	Chief Executive Officer	56	20-02-25
Mike Mason DFI	Director of Finance/CFO	49	19-02-24
Amama Sadiq CTO	Chief Tech/Sci/R&D Officer	-	23-03-31
Accumanno James CMP	Compliance Officer	-	21-04-30
Reshma Rangwala CTO	Chief Tech/Sci/R&D Officer	46	22-03-31
Elhan Webb IRC	Investor Relations Contact	-	22-03-13
Lisa DiPaolo HRO	Human Resources Officer	-	22-08-31
Stuart Poulton PRN	Corporate Officer/Principal	51	22-01-31
Sohanya Cheng PRN	Corporate Officer/Principal	41	21-06-07
Michael Mano LAW	General Counsel	47	20-12-14

Members of the board	Title	Age	Since
Garen Bohlin BRD	Director/Board Member	76	13-10-02
Barry Greene BRD	Director/Board Member	60	12-12-31
Deepa Pakianathan BRD	Director/Board Member	59	13-03-31
Chen Schor BRD	Director/Board Member	51	20-11-24
Mansoor Mirza BRD	Director/Board Member	63	10-09-30
Richard Paulson CEO	Chief Executive Officer	56	20-02-25
Christy Oliger BRD	Director/Board Member	54	20-08-27
Su Zhen BRD	Director/Board Member	47	23-08-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	116,465,736	108,093,698 ( 92.81 %)	0	92.81 %

Name	Equities	%	Valuation
BlackRock Advisors LLC 8.219 %	9,457,310	8.219 %	14 M $
Vanguard Fiduciary Trust Co. 7.570 %	8,710,158	7.570 %	13 M $
Avidity Partners Management LP 7.212 %	8,298,570	7.212 %	13 M $
Palo Alto Investors LP 4.434 %	5,102,193	4.434 %	8 M $
Chione Ltd. 3.824 %	4,400,000	3.824 %	7 M $
Citadel Advisors LLC (13f Subfiler) 2.695 %	3,101,399	2.695 %	5 M $
Geode Capital Management LLC 2.070 %	2,382,428	2.070 %	4 M $
GSA Capital Partners LLP 2.032 %	2,337,985	2.032 %	4 M $
STATE STREET CORPORATION 1.785 %	2,053,773	1.785 %	3 M $
Renaissance Technologies LLC 1.707 %	1,964,377	1.707 %	3 M $

Karyopharm Therapeutics, Inc.

85 Wells Avenue Suite 210, 2nd floor

02459-3298, Newton

+617 658 0600

http://www.karyopharm.com

address Karyopharm Therapeutics Inc.(KPTI)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.22 USD

Average target price

5.571 USD

Spread / Average Target

+356.67%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
KARYOPHARM THERAPEUTICS INC.	+33.53%	140M
VERTEX PHARMACEUTICALS INCORPORATED	-2.34%	102B
REGENERON PHARMACEUTICALS, INC.	+2.31%	97.22B
ARGENX SE	+4.22%	22.27B
BIONTECH SE	-16.72%	20.84B
GENMAB A/S	-4.50%	19.19B
WUXI APPTEC CO., LTD.	-41.75%	16.76B
BEIGENE, LTD.	-23.26%	14.76B
NEUROCRINE BIOSCIENCES, INC.	-0.02%	13.54B
SAREPTA THERAPEUTICS, INC.	+22.69%	11.53B

Bio Therapeutic Drugs